SCYNEXIS (NASDAQ:SCYX – Get Free Report) and Liquidia (NASDAQ:LQDA – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.
Earnings and Valuation
This table compares SCYNEXIS and Liquidia”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| SCYNEXIS | $19.22 million | 1.90 | -$8.61 million | ($2.09) | -1.75 |
| Liquidia | $158.32 million | 19.30 | -$68.92 million | $1.37 | 24.91 |
SCYNEXIS has higher earnings, but lower revenue than Liquidia. SCYNEXIS is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of current recommendations for SCYNEXIS and Liquidia, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| SCYNEXIS | 1 | 0 | 2 | 0 | 2.33 |
| Liquidia | 2 | 4 | 5 | 1 | 2.42 |
SCYNEXIS presently has a consensus target price of $33.00, suggesting a potential upside of 801.64%. Liquidia has a consensus target price of $72.85, suggesting a potential upside of 113.44%. Given SCYNEXIS’s higher probable upside, analysts clearly believe SCYNEXIS is more favorable than Liquidia.
Volatility and Risk
SCYNEXIS has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.
Profitability
This table compares SCYNEXIS and Liquidia’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| SCYNEXIS | N/A | -44.15% | -32.61% |
| Liquidia | 30.74% | 149.65% | 36.30% |
Institutional & Insider Ownership
54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
Liquidia beats SCYNEXIS on 12 of the 15 factors compared between the two stocks.
About SCYNEXIS
SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
About Liquidia
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion. The company also a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
Receive News & Ratings for SCYNEXIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS and related companies with MarketBeat.com's FREE daily email newsletter.
